Hospitals in Yucatán will be able to detect early symptoms of both Type 2 Diabetes Mellitus and the Metabolic Syndrome through a new technological instrument. Therefore, it will contribute to decrease the index of consequences caused by these two diseases, thus, improving one’s life quality.
As reported by UnoTV, the company Bibliotecas Genómicas (Essenx, by its trade name), is one of the Development Program for the Software Industry (PROSOFT) beneficiaries. They operate with federal and state resources through the Secretariat of Economic Development (Sefoe ). The firm’s CEO, Javier Eduardo Apodaca Hernández, explained that since its foundation in 2013, Essenx has been developing high-tech products that allow monitoring the patient’s health from a genomic approach, a strategy that assists traditional care.
“Thanks to the support received, the company has started the project called ‘Early Detection Tool for Metabolic Anomalies’ related to Metabolic Syndrome (MS) and Type 2 Diabetes Mellitus (DMT2) in the Yucatan Peninsula,” he said.
The project’s aim is to offer people a low cost tool to detect these deseases in their early symptoms stage. Thus, it will identify candidate genetic biomarkers for the hybridization probes (DNA or RNA fragments) design; using “big data” strategies and Next Generation Sequencing (NGS) techniques. Apodaca Hernández detailed that this will result in a patient’s screening to determine if they need further specific tests in regards of metabolism anomalities due to DMT2 or SM.
With this project, the company will contribute to position Yucatán as a pioneer state in the development of biotechnological tools for the detection of Type 2 Diabetes Mellitus.
SOURCE: UnoTv